CureVac NV (CVAC)

Stay updated with CureVac NV (CVAC) share price analysis and insights to guide your investment strategy. Stay informed with FP Markets Singapore.

Pricing is indicative. Past performance is not a reliable indicator of future results. Log in to see latest markets data.

CureVac NV (CVAC) Profile

CureVac N.V., a clinical-stage biopharmaceutical firm, is focused on the development of a diverse range of revolutionary therapies based on messenger ribonucleic acid (mRNA). It is working to develop prophylactic vaccines, including CV7202, a prophylactic mRNA-based vaccine candidate against COVID-19; a vaccine for lassa yellow fever; a vaccine for the respiratory syncytial virus; CV7301, a second-generation lipid nanoparticle flu vaccine; and immunisations against Rota, malaria, and universal influenza. Additionally, the company is developing RNA-based cancer immunotherapies, comprising ofCV8102 (BI 1361849), a self-adjuvanting mRNA vaccine in Phase 1 clinical trials for non-small cell lung cancer, and also tumour-associated antigens and shared neo-antigens. Additionally, the company is developing protein-based therapeutics for Cas9 gene editing, ophthalmic and respiratory illnesses, as well as therapeutic antibodies. The headquarters of the corporation are in T14 Bingen, Germany. Full Time Employees: 455 latest stock price29.860.00 (0.00%) At close: 04:00 PM as at 1/12/2022 EST. Market cap 5,585B USD. CureVac total assets for the quarter ending September 30, 2021, were $1.588B.

CureVac NV (CVAC.xnas) News
CureVac is developing CV2CoV, a preclinical second-generation mRNA vaccine potential, against SARS-CoV-2 in partnership with GlaxoSmithKline Plc (NYSE: GSK). In Q1 2022, the business plans to initiate a Phase 1 trial evaluating CV2CoV.

Start Trading CureVac NV (CVAC) with a Market Leader Today

CureVac NV (CVAC) Trading FAQ

Shares represent units of ownership within a company. Shares are also known as stocks or equities. Dividend payments are common with some companies, a method of sharing company profits with shareholders. In addition to traditional share dealing, however, traders can access derivatives: trading instruments derived from the movement of an underlying share price.

Individual stock CFDs (contract for differences) fall under the umbrella of derivative products, an effective low-cost trading vehicle. While CFDs do not grant shareholder privileges, active CFD positions may receive a dividend if executed before the ex-dividend date.

Start Trading
in minutes

Get instant Updates in Telegram